2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. 1246566-47-1

1246566-47-1

YLT192 Chemical Structure

1246566-47-1

Chemical Structure

  • YLT192
  • CAS No: 1246566-47-1
    Formula: C21H19N3O4
    Molecular Weight: 377.39
  • IUPAC Name: 4-(4-(3-methoxybenzamido)phenoxy)-N-methylpicolinamide
  • InChIKey: VEAFCVREGPWSCO-UHFFFAOYSA-N
  • SMILES: O=C(NC)C1=NC=CC(OC2=CC=C(C=C2)NC(C3=CC=CC(OC)=C3)=O)=C1

Biological Activity: YLT192 is an orally active and highly bioavailable VEGFR2 inhibitor with potent anti-angiogenic activity and anti-tumor efficacy. YLT192 significantly inhibited the kinase activity of VEGFR2 and inhibited the proliferation, migration, invasion and tube formation of human umbilical cord vascular endothelial cells. YLT192 also inhibited VEGF-induced VEGFR2 phosphorylation and its downstream signaling regulators. YLT192 also showed the ability to inhibit angiogenesis in vivo in zebrafish embryo models and alginate-coated tumor cell experiments. YLT192 can directly inhibit the proliferation of cancer cells and induce their apoptosis[1].

Cat. No. Product Name Purity Description
HY-116452 YLT192 YLT192 is an orally active and highly bioavailable VEGFR2 inhibitor with potent anti-angiogenic activity and anti-tumor efficacy. YLT192 significantly inhibited the kinase activity of VEGFR2 and inhibited the proliferation, migration, invasion and tube formation of human umbilical cord vascular endothelial cells. YLT192 also inhibited VEGF-induced VEGFR2 phosphorylation and its downstream signaling regulators. YLT192 also showed the ability to inhibit angiogenesis in vivo in zebrafish embryo models and alginate-coated tumor cell experiments. YLT192 can directly inhibit the proliferation of cancer cells and induce their apoptosis.

References

[1]. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models

Keywords:

YLT192